152 related articles for article (PubMed ID: 3872709)
1. Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.
Liberati AM; Brugia M; Edwards BS; Bertoni P; Ballatori E; Puxeddu A; Grignani F
Cancer Immunol Immunother; 1985; 19(2):136-41. PubMed ID: 3872709
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission.
Liberati AM; Ballatori E; Fizzotti M; Schippa M; Cini L; Cinieri S; Proietti MG; Di Marzio R; Senatore M; Grignani F
Cancer Immunol Immunother; 1988; 26(1):87-93. PubMed ID: 3125973
[TBL] [Abstract][Full Text] [Related]
3. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bertotto A; Spinozzi F; Bracaglia AM; Falini B; Davis S
Cancer; 1982 Aug; 50(3):490-7. PubMed ID: 7046903
[TBL] [Abstract][Full Text] [Related]
4. The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. Correlation of skin reactivity and leukocyte migration-inhibition factor in the sera of anergic subjects.
Velardi A; Rambotti P; Cernetti C; Spinozzi F; Bertotto A; Martelli MF
Thymus; 1983 Sep; 5(5-6):429-32. PubMed ID: 6362105
[TBL] [Abstract][Full Text] [Related]
5. Immunopathology of non-Hodgkin lymphomas.
Huber H; Gattringer C; Knapp W; Stein H
Klin Wochenschr; 1984 Nov; 62(21):1001-10. PubMed ID: 6392723
[TBL] [Abstract][Full Text] [Related]
6. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. A report from the Italian Lymphoma Study Group (GISL).
Federico M; Gobbi PG; Moretti G; Avanzini P; Di Renzo N; Cavanna L; Ascari E; Silingardi V
Am J Clin Oncol; 1995 Feb; 18(1):8-14. PubMed ID: 7847265
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.
Gupta S; Fernandes G
Clin Exp Immunol; 1981 Jul; 45(1):205-14. PubMed ID: 6975681
[TBL] [Abstract][Full Text] [Related]
8. Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease.
Fuks Z; Strober S; Bobrove AM; Sasazuki T; McMichael A; Kaplan HS
J Clin Invest; 1976 Oct; 58(4):803-14. PubMed ID: 135001
[TBL] [Abstract][Full Text] [Related]
9. In vitro lymphocyte dysfunction in Hodgkin's disease.
Graze PR; Perlin E; Royston I
J Natl Cancer Inst; 1976 Feb; 56(2):239-43. PubMed ID: 130496
[TBL] [Abstract][Full Text] [Related]
10. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Bernengo MG; Fra P; Lisa F; Meregalli M; Zina G
Clin Immunol Immunopathol; 1983 Sep; 28(3):311-24. PubMed ID: 6603936
[TBL] [Abstract][Full Text] [Related]
11. T-lymphocyte subsets in human lymph nodes: relative increase of OKT-8+ cells in neoplastic and reactive B-cell proliferation.
Ruco LP; Stoppacciaro A; Valtieri M; Uccini S; Vitolo D; Baroni CD
Clin Immunol Immunopathol; 1984 Mar; 30(3):337-45. PubMed ID: 6607799
[TBL] [Abstract][Full Text] [Related]
12. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
[TBL] [Abstract][Full Text] [Related]
13. Immunological study of patients with Hodgkin's disease in long-lasting not-maintained complete remission.
Gobbi M; Fiacchini M; Tomasini I; Ruggero D; Lauria F; Tura S
Boll Ist Sieroter Milan; 1977 Mar; 56(2):144-51. PubMed ID: 326273
[TBL] [Abstract][Full Text] [Related]
14. Subsets of lymphoid cells in blood and thymus in myasthenia gravis. Monoclonal antibody analysis.
Fujii N; Itoyama Y; Tabira T; Kuroiwa Y
J Neuroimmunol; 1983 Jun; 4(3):151-9. PubMed ID: 6343429
[TBL] [Abstract][Full Text] [Related]
15. Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year.
Moncada E; Subirá ML; Oleaga A; Goñi F; Sánchez-Ibarrola A; Monreal M; Sevilla M; Goñi MJ; Yoldi A; Terán D
J Autoimmun; 1990 Oct; 3(5):625-38. PubMed ID: 2252531
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's lymphoma phenotyping: problems in the use of heterologous and monoclonal antibodies.
Barcos M; Minowada J; Minato K; Pollard C; Cancino M; Han T; Henderson E; Ozer H
Leuk Res; 1983; 7(4):523-37. PubMed ID: 6604849
[TBL] [Abstract][Full Text] [Related]
17. Immunologic profile in patients with Hodgkin's disease in complete remission.
Liberati AM; Ballatori E; Fizzotti M; Schippa M; Proietti MG; Di Marzio R; Pecci A; Biscetti L; Sbarretti R; Cini L
Cancer; 1987 Jun; 59(11):1906-13. PubMed ID: 3105863
[TBL] [Abstract][Full Text] [Related]
18. Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease.
Romagnani S; Del Prete GF; Maggi E; Bellesi G; Biti G; Rossi Ferrini PL; Ricci M
J Clin Invest; 1983 May; 71(5):1375-82. PubMed ID: 6602150
[TBL] [Abstract][Full Text] [Related]
19. Possible nonspecific immunopotentiation by 2,4-dinitrochlorobenzene sensitization in patients with Hodgkin's disease.
Rubinstein A; Ghossein NA; Melamed J; Bosworth JL; Murphy RA
Oncology; 1979; 36(1):23-6. PubMed ID: 313034
[TBL] [Abstract][Full Text] [Related]
20. Interaction between serum factors and T lymphocytes in Hodgkin's disease. Use as a diagnostic test.
Fuks Z; Strober S; Kaplan HS
N Engl J Med; 1976 Dec; 295(23):1273-8. PubMed ID: 185517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
